Immune response to the hepatitis B antigen in the RTS,S/AS01 malaria vaccine, and co-administration with pneumococcal conjugate and rotavirus vaccines in African children: A randomized controlled trial

• Main Authors: Innocent Valéa (Author), Samuel Adjei (Author), Effua Usuf (Author), Ousmane Traore (Author), Daniel Ansong (Author), Halidou Tinto (Author), Harry Owusu Boateng (Author), Amanda Leach (Author), Athanase Mwinessobaonfou Some (Author), Patrick Buabeng (Author), Johan Vekemans (Author), Louis Arnaud Nana (Author), Amos Kotey (Author), Pascale Vandoolaeghe (Author), Florence Ouedraogo (Author), David Sambian (Author), Marc Lievens (Author), Marc Christian Tahita (Author), Theresa Rettig (Author), Erik Jongert (Author), Palpouguini Lompo (Author), Ali Idriss (Author), Dorota Borys (Author), Sayouba Ouedraogo (Author), Frank Prempeh (Author), Md Ahsan Habib (Author), Lode Schuerman (Author), Hermann Sorgho (Author), Tsiri Agbenyega (Author)
• Format: Book
• Published: Taylor & Francis Group, 2018-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The RTS,S/AS01 malaria vaccine (Mosquirix) reduces the incidence of Plasmodium falciparum malaria and is intended for routine administration to infants in Sub-Saharan Africa. We evaluated the immunogenicity and safety of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate...